AxoGen, Inc. (NASDAQ:AXGN) Shares Acquired by Geode Capital Management LLC

Geode Capital Management LLC grew its holdings in shares of AxoGen, Inc. (NASDAQ:AXGN - Free Report) by 3.2% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,010,508 shares of the medical equipment provider's stock after buying an additional 31,612 shares during the period. Geode Capital Management LLC owned 2.30% of AxoGen worth $14,170,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in the business. Barclays PLC boosted its holdings in shares of AxoGen by 119.3% in the 3rd quarter. Barclays PLC now owns 72,036 shares of the medical equipment provider's stock valued at $1,010,000 after buying an additional 39,182 shares in the last quarter. State Street Corp lifted its position in AxoGen by 11.9% in the third quarter. State Street Corp now owns 896,674 shares of the medical equipment provider's stock valued at $12,571,000 after acquiring an additional 95,051 shares during the last quarter. Point72 Asset Management L.P. acquired a new position in AxoGen in the third quarter valued at $240,000. Parkman Healthcare Partners LLC purchased a new position in shares of AxoGen during the third quarter worth about $5,789,000. Finally, Verition Fund Management LLC increased its position in shares of AxoGen by 41.0% during the third quarter. Verition Fund Management LLC now owns 40,860 shares of the medical equipment provider's stock worth $573,000 after purchasing an additional 11,874 shares in the last quarter. 80.29% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, StockNews.com raised AxoGen from a "hold" rating to a "buy" rating in a research report on Tuesday, October 15th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $15.00.

AxoGen Stock Performance

NASDAQ AXGN traded down $0.01 during trading on Tuesday, reaching $16.48. The company's stock had a trading volume of 589,798 shares, compared to its average volume of 392,300. AxoGen, Inc. has a twelve month low of $5.55 and a twelve month high of $17.23. The firm has a market cap of $725.25 million, a price-to-earnings ratio of -51.50 and a beta of 1.06. The business's fifty day moving average price is $14.25 and its 200-day moving average price is $12.17. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.47 and a current ratio of 3.74.

About AxoGen

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.